Amphastar Pharmaceuticals Inc. logo

Amphastar Pharmaceuticals Inc.

AMPH | NASDAQ
Chart Builder DCF Calculator
$24.75
+$0.27 (+1.10%)
Sep 22, 2026, 12:23 PM ET · Market open

Company Profile

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Key Executives

Name Position
Yongfeng Zhang Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director
William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director
Ziping Luo Chairman of the Board, Chief Scientist & Chief Operating Officer
Dan Dischner Senior Vice President of Human Resources & Corporate Communication
Jacob Liawatidewi Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Rong Zhou Senior EVice President of Production & EVP of Scientific Affairs
Tony Marrs Executive Vice President of Regulatory Affairs & Clinical Operations

Latest SEC Filings

Date Type Title
Sep 03, 2026 4 Filing
Aug 12, 2026 4 Filing
Aug 11, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 13, 2026 4 Filing
Jul 13, 2026 3 Filing
Jul 13, 2026 8-K Current Report
Jul 08, 2026 8-K Current Report
View All SEC Filings
Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc. logo
Country United States
IPO Date Jun 24, 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,976
CEO Yongfeng Zhang

Contact Details

11570 6th Street Rancho Cucamonga, California 91730 United States

Stock Details

Ticker Symbol AMPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001297184
CUSIP Number 03209R103
ISIN Number US03209R1032
SIC Code 2834

© 2026 bestshares.com. All rights reserved.